Adial Pharmaceuticals (NASDAQ:ADIL) Upgraded at Maxim Group

Maxim Group upgraded shares of Adial Pharmaceuticals (NASDAQ:ADIL) from a hold rating to a buy rating in a report released on Tuesday, Marketbeat.com reports. The firm currently has $1.50 target price on the stock.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, July 26th. Zacks Research lowered shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $4.75.

Adial Pharmaceuticals Trading Up 8.6%

NASDAQ:ADIL opened at $0.40 on Tuesday. The stock has a 50 day moving average of $0.39 and a 200-day moving average of $0.51. The firm has a market capitalization of $8.78 million, a PE ratio of -0.38 and a beta of 1.36. Adial Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $1.30.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. As a group, analysts predict that Adial Pharmaceuticals will post -1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Adial Pharmaceuticals

An institutional investor recently raised its position in Adial Pharmaceuticals stock. Citadel Advisors LLC boosted its holdings in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 63.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,508 shares of the company’s stock after purchasing an additional 21,238 shares during the period. Citadel Advisors LLC owned approximately 0.85% of Adial Pharmaceuticals worth $55,000 at the end of the most recent quarter. 16.41% of the stock is owned by institutional investors and hedge funds.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.